Indications
Rienso is indicated for the intravenous treatment of iron-deficiency anaemia in adult patients with chronic kidney disease (CKD). The diagnosis of iron deficiency must be based on appropriate laboratory tests (see section 4.2).
Composition
- Active substance
- Ferumoxytol
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rienso
- Active substance
- Ferumoxytol
- ATC code
- B03
- Therapeutic area
- Anemia, Kidney Failure, Chronic
- Marketing authorisation holder
- Takeda Pharma A/S
- Status
- Withdrawn